Optimising treatment of bone metastases by Aredia™ and Zometa™
- 105 Downloads
Metastatic bone disease develops as a result of the many interactions between tumour cells and bone cells. This leads to disruption of normal bone metabolism, with the increased osteoclast activity seen in most, if not all, tumor types providing a rational target for treatment. The clinical course of metastatic bone disease in multiple myeloma, breast and prostate cancers is relatively long, with patients experiencing sequential skeletal complications over a period of several years. These include bone pain, fractures, hypercalcaemia, and spinal cord compression, all of which may profoundly impair a patient’s quality of life.
External beam radiotherapy and systemic endocrine and cytotoxic treatments are the mainstay of treatment in advanced cancers. However, it is now clear that the bisphosphonates provide an additional treatment strategy, which reduces both the symptoms and complications of bone involvement. Pamidronate (Aredia™) is the most widely evaluated bisphosphonate and is recommended for most patients with multiple myeloma or breast cancer with bone metastases. Current research aims include the evaluation of new potent bisphosphonates such as zoledronic acid (Zometa™). It is hoped that this compound is not only more convenient and easier to administer but also more effective in inhibiting skeletal morbidity. Zometa may also have some direct anticancer activity.
Preclinical studies with Zometa have demonstrated its potential in malignant bone disease. Clinical studies in treatment of hypercalcemia of malignancy have been completed, as have Phase I and II trials in patients with cancer and pre-existing bone metastases. Three randomized, double-blind, controlled Phase III trials are now ongoing to establish the efficacy and safety of Zometa in treatment of bone metastases in patients with osteolytic and osteoblastic lesions. Additionally, new specific molecules such as osteoprotogerin have been developed that are based on our improved understanding of the cellular signalling mechanisms involved in cancer induced bone disease. These potent molecules are now entering clinical trials.
Ongoing research is aimed at trying to define the optimum route, dose, schedule and type of bisphosphonate in metastatic bone disease and their use in the prevention and treatment of osteoporosis in cancer patients. In vitro suggestions of direct anti-cancer activity and some promising clinical data in early breast cancer have resulted in considerable interest in the possible adjuvant use of bisphosphonates to inhibit the development of bone metastases.
Key wordsBone metastases Bisphosphonates Pamidronate Zoledronic acid
Unable to display preview. Download preview PDF.
- 6).Coleman RE: Pamidronate Disodium in the treatment and management of hypercalcaemia.Reviews in Contemporary Pharmacotherapy 9:147–164, 1998.Google Scholar
- 8).Body JJ, Lichinitser MR, Diehl IE,et al: Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone. Proceedings ASCO 18:575a, 1999.Google Scholar
- 9).Berenson JR, Lipton A, Rosen LS,et al: Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), inpatients with osteolytic bone metastases.Blood 88 (Suppl 1): 586a, 1998.Google Scholar
- 11).Coleman RE: Biochemical markers of malignant bone disease. Rubens RD & Mundy GR eds, Martin Dunitz, London, 2000, in press.Google Scholar
- 20).Lipton A, Theriault RL, Hortobagyi GN,et al: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast cancer and osteolytic bone metastases: long-term results of two randomised, placebo-controlled trials.Cancer 88:1082–1090, 2000.PubMedCrossRefGoogle Scholar
- 22).Bare S, Kimmel D, Binkley N,et al: Zoledronate (CGP-42′446) suppresses turnover without affecting mineralization in cancellous bone of the ovariec-tomized non-human primate.J Bone Miner Res 12 (suppll): S473, 1997Google Scholar
- 23).Green JR, Hornby SB, Evans GP,et al: Effect of 1-year treatment with zoledronate (CGP 42446) on bone mineral density, bone mechanical properties, and biochemical markers in the ovariectomized rat.J Bone Miner Res Abstract M631, 1996.Google Scholar
- 26).Major P, Lortholary A, Hon J,et al: Zoledronic acid is superior to pamidronate in the treatment of tumourinduced hypercalcaemia: A pooled analysis.ASCO Proceedings 19:604a, 2000.Google Scholar
- 29).Powles TJ, Paterson AHG, Nevantaus A,et al: Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer.ASCO Proceedings 17:468a, 1998.Google Scholar
- 31).Saarto T, Blomqvist C, Virkkunen P,et al: No reduction of bone metastases with adjuvant clodronate treatment in node-positive breast cancer patients.ASCO Proceedings 18:128a, 1999.Google Scholar
- 32).Fisher B, Redmond C, Legault-Poisson S,et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positivenode breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the NSABP-16.J Clin Oncol 8:1005–1018, 1990PubMedGoogle Scholar
- 33).Fisher B, Brown A, Dimitrov N,et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen non-responsive tumors: Results from NSABP B-15.J Clin Oncol 8:1483–1496, 1990PubMedGoogle Scholar
- 35).Rubens R, Coleman R: Bone metastases. In: Abeloff et al eds, Clinical Oncology, Churchill Livingston, Inc., New York, pp643–665, 1995.Google Scholar
- 37).Percival RC, Urwin GH, Watson ME: Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.Eur J Surg Oncol 113:41–49, 1987.Google Scholar